Exhibit 99.1

CONTACT:
              Gary S. Maier
              Maier & Company, Inc.
              (310) 442-9852

      CYTOMEDIX AND HARVEST TECHNOLOGIES SETTLE PATENT DISPUTE

ROCKVILLE, Maryland - May 24, 2005 - Cytomedix, Inc. (OTC BB:CYME.OB) today
announced that it and Harvest Technologies Inc., located in Plymouth,
Massachusetts, have resolved a patent dispute related to the litigation between
them to the mutual satisfaction of both companies. The two companies have agreed
to dismiss the lawsuit, and a license has been granted to Harvest as part of the
settlement.

"This settlement follows two other significant licensing agreements announced
recently and it represents yet another important milestone in Cytomedix's
growth," said Dr. Kshitij Mohan, chief executive officer of Cytomedix. "We are
pleased to settle this dispute and will continue to defend our intellectual
property vigorously. At the same time, we will aggressively seek opportunities
to share our technology with partners who can expand the market for platelet-gel
therapy in a variety of clinical applications. We believe that there is a
critical clinical need in the wound care market that may be further addressed by
this technology."

He added that Cytomedix is continuing to conduct its own multi-center,
prospective, randomized, blinded and controlled clinical trial on diabetic foot
ulcers utilizing its autologous platelet releasate therapy. The company recently
announced the completion of patient enrollment in that trial. "At the same time,
we will continue to seek opportunities to negotiate agreements with other
medical device manufacturers and health care organizations that are interested
in licensing our technology because that will allow a more rapid availability of
products based on this technology to a larger number of patients who may benefit
from it," Mohan said.

"Cytomedix will also seek further opportunities to enforce its patents, through
the courts if needed, supported by a team of well-respected attorneys from
several leading law firms who are working with us on a contingency-fee basis,"
Mohan added.

About Cytomedix

Cytomedix, Inc. is a biotechnology company specializing in processes and
products derived from autologous platelet releasates for uses in the treatment
of wounds and other applications. The current offering is the AutoloGel(tm)
system, a technology that utilizes an autologous platelet gel composed of
multiple growth factors and fibrin matrix. The company is conducting a well-
controlled, blinded, prospective, multi-center clinical trial on the use of its
technology in healing diabetic foot ulcers. Cytomedix is working with healthcare
providers to offer an advanced therapy at the point-of-care in multiple
settings. Additional information is available at: http://www.cytomedix.com.




Forward Looking Statements

Statements contained in this press release not relating to historical facts are
forward-looking statements that are intended to fall within the safe harbor rule
for such statements under the Private Securities Litigation Reform Act of 1995.
The information contained in the forward-looking statements is inherently
uncertain, and Cytomedix's actual results may differ materially due to a number
of factors, many of which are beyond Cytomedix's ability to predict or control,
including among others, the success of new sales initiatives, governmental
regulation, acceptance by the medical community and competition. The increases
in the revenues to be received over the life of the patents from the future
sales of covered products by Harvest Technologies, other licensees or Cytomedix
is also uncertain. These forward-looking statements are subject to known and
unknown risks and uncertainties that could cause actual events to differ from
the forward-looking statements. More information about some of these risks and
uncertainties may be found in the reports filed with the Securities and Exchange
Commission by Cytomedix, Inc.

                               #    #    #